Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines.
about
Potential strategies and biosafety protocols used for dual-use research on highly pathogenic influenza virusesAdvances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesProtective efficacy of a high-growth reassortant swine H3N2 inactivated vaccine constructed by reverse genetic manipulationCross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles.Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies.A plant-produced H1N1 trimeric hemagglutinin protects mice from a lethal influenza virus challenge.A baseline process for the production, recovery, and purification of bacterial influenza vaccine candidates.Different immunity elicited by recombinant H5N1 hemagglutinin proteins containing pauci-mannose, high-mannose, or complex type N-glycansIdentification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin.Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates.A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection.Activated human nasal epithelial cells modulate specific antibody response against bacterial or viral antigens.Immunogenicity and efficacy of fowlpox-vectored and inactivated avian influenza vaccines alone or in a prime-boost schedule in chickens with maternal antibodies.Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses.Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?Progress on adenovirus-vectored universal influenza vaccines.Addition of αGal HyperAcute™ technology to recombinant avian influenza vaccines induces strong low-dose antibody responsesExploration of the BF2*15 major histocompatibility complex class I binding motif and identification of cytotoxic T lymphocyte epitopes from the H5N1 influenza virus nucleoprotein in chickens.Development of an influenza virus protein array using Sortagging technology.A nonfusogenic antigen mimic of influenza hemagglutinin glycoproteins constituted with soluble full-length HA1 and truncated HA2 proteins expressed in E. coli.Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses.Single Dose of Consensus Hemagglutinin-Based Virus-Like Particles Vaccine Protects Chickens against Divergent H5 Subtype Influenza Viruses.How can we develop universal H5N1 vaccines.Influenza Viral Vectors Expressing Two Kinds of HA Proteins as Bivalent Vaccine Against Highly Pathogenic Avian Influenza Viruses of Clade 2.3.4.4 H5 and H7N9.
P2860
Q26825532-1CD4A56F-020F-4113-9076-ECAFCEDEF123Q27013568-AF3A33CE-0236-476E-B2CE-EF582ED469A7Q28394975-A1C24804-8EBD-4179-8143-5C29ADC3F6C0Q30374446-8B3376A8-1657-4B33-AC4B-EC401E7031B2Q30418340-35269731-6458-4664-B948-628902FCD6FAQ30420990-9E2D7B2A-AA00-471C-82E2-F25A53651AA6Q30425590-3D390D36-94BB-4286-B92B-D361321C3DD6Q30431659-85D9AEE1-9010-4848-AB07-83DC0C672A75Q30432386-C5C6A9CD-1667-473F-BDB6-746EE3AC7D27Q30535722-3823DF5D-1565-4CBC-96B0-4A1A92AD0073Q33809953-E64B9B1E-45CD-460D-A50E-EBEF39DD1CFAQ34395834-171E3322-476C-46A4-A873-8A2FD3DE67AAQ34548282-C7917FA5-01D2-4145-9A30-667247EE224AQ34584253-923192CC-3F95-4045-BA88-45DC1861E570Q34643285-941BD783-560E-414E-954F-C32F1BD9CDBFQ35132253-07795E6B-5012-4E4F-8A77-10FD608A3423Q35664854-5AD3550B-D833-464B-B1A3-2112ABC596A9Q38421971-6DAF219E-1A8F-4C16-B19D-5DD43907BA73Q38634936-D5E544DA-94EA-460E-BBC0-5B62EEC3D006Q38752281-714DBB49-953A-4A13-A00D-C9C7F92C0962Q39346763-B5F9DCA2-D8C0-4C7D-86E9-3DEEEFFEC1CBQ42184367-875F75A3-1BE9-4525-AD28-AC994B175691Q42286975-E67BE39F-4EC4-4990-BC0C-4670764EEB9BQ47157586-7AAB7882-5923-41A9-A24C-3A705E8FD955Q50948360-A1F804B9-2B0C-4E6B-AA5A-3B4BBC0394B9Q53829188-A057CD55-A83F-4431-A4E6-7C5A184F90C5
P2860
Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Recombinant trimeric HA protei ...... ivated or adenovirus vaccines.
@ast
Recombinant trimeric HA protei ...... ivated or adenovirus vaccines.
@en
type
label
Recombinant trimeric HA protei ...... ivated or adenovirus vaccines.
@ast
Recombinant trimeric HA protei ...... ivated or adenovirus vaccines.
@en
prefLabel
Recombinant trimeric HA protei ...... ivated or adenovirus vaccines.
@ast
Recombinant trimeric HA protei ...... ivated or adenovirus vaccines.
@en
P2093
P2860
P1433
P1476
Recombinant trimeric HA protei ...... ivated or adenovirus vaccines.
@en
P2093
Pei-Chun Tsou
Pele Chong
Shih-Chang Lin
Suh-Chin Wu
P2860
P304
P356
10.1371/JOURNAL.PONE.0020052
P407
P577
2011-05-31T00:00:00Z